Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Toddlers : Open-Label Extension to EPITOPE

The open-label extension (OLE) of the EPITOPE study provides promising results for the treatment of peanut allergies in young children. Epicutaneous immunotherapy with the VIASKIN® patch (VP250) showed a steady increase in tolerance to peanut proteins over two years - over 80% of the children treated were able to tolerate significantly larger amounts at the end of the study. Particularly pleasing: there were no serious side effects or anaphylactic reactions in the treatment group. Children who initially received placebo and were later treated with VP250 also showed similar progress. Prim. Assoc. Prof. PD Dr. Thomas Eiwegger was part of the team of authors. 

Greenhawt, M., Albright, D., Anvari, S., Arends, N., Arkwright, P. D., Bégin, P., Blümchen, K., Brown-Whitehorn, T., Cassell, H., Chan, E. S., Ciaccio, C. E., Deschildre, A., Divaret-Chauveau, A., Dorris, S., Dorsey, M., Du Toit, G., Eiwegger, T., Erlewyn-Lajeunesse, M., Fleischer, D. M., ... Burks, A. W. (2025). Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Toddlers: Open-Label Extension to EPITOPE. Journal of Allergy and Clinical Immunology: In Practice. Advance online publication. https://doi.org/10.1016/j.jaip.2025.02.004